Type B adverse drug reactions reported by an immunoallergology department
Objective: Characterization of the adverse drug reactions (ADR) reported by the immunoallergology department (IAD), Centro Hospitalar de São João (Porto), to the Northern Pharmacovigilance Centre (NPC). Methods: An observational, descriptive and retrospective study was conducted, based in a spontan...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2018-03-01
|
| Series: | Pharmacy Practice |
| Subjects: | |
| Online Access: | https://www.pharmacypractice.org/journal/index.php/pp/article/view/1070/608 |
| _version_ | 1819110062592884736 |
|---|---|
| author | Costa MJ Herdeiro MT Polónia JJ Ribeiro-Vaz I Botelho C Castro E Cernadas J. |
| author_facet | Costa MJ Herdeiro MT Polónia JJ Ribeiro-Vaz I Botelho C Castro E Cernadas J. |
| author_sort | Costa MJ |
| collection | DOAJ |
| description | Objective: Characterization of the adverse drug reactions (ADR) reported by the immunoallergology department (IAD), Centro Hospitalar de São João (Porto), to the Northern Pharmacovigilance Centre (NPC).
Methods: An observational, descriptive and retrospective study was conducted, based in a spontaneous report system. Participants were all the patients from the IAD, with suspected ADR, reported to NPC by specialists after the study was completed.
Results: Studied population had a median age of 41 years, with the predominance of the female gender (73.2%). Allergic rhinitis and asthma were the most frequent comorbidities. All studied ADR were type B, 89.6% were serious, 86.4% unexpected and 2.6% associated with drugs that presented less than 2 years in the market. The most represented drug classes were the non-steroidal anti-inflammatory drugs (NSAIDs) (52.6%) and antibiotics (25.2%). Skin symptoms represented 61.2% of the reported complaints. About 52.9% of these ADR occurred in less than one hour after intake. The most frequent ADR treatment at the time of the reaction was drug interruption (86.2%), followed by the prescription of anti-histamines (42.2%).
Conclusions: Reported ADR to NPC by the Drug Alert Unit were mainly serious, unexpected, associated with NSAIDs and antibiotics and related with marketing authorization medicines older than two years. These results could be very useful to develop strategies to prevent the clinical and economic consequences of ADR. |
| first_indexed | 2024-12-22T03:35:45Z |
| format | Article |
| id | doaj.art-e4de4e15cfaa47efb6799e0133fb08c1 |
| institution | Directory Open Access Journal |
| issn | 1885-642X 1886-3655 |
| language | English |
| last_indexed | 2024-12-22T03:35:45Z |
| publishDate | 2018-03-01 |
| publisher | Centro de Investigaciones y Publicaciones Farmaceuticas |
| record_format | Article |
| series | Pharmacy Practice |
| spelling | doaj.art-e4de4e15cfaa47efb6799e0133fb08c12022-12-21T18:40:23ZengCentro de Investigaciones y Publicaciones FarmaceuticasPharmacy Practice1885-642X1886-36552018-03-01161107010.18549/PharmPract.2018.01.1070Type B adverse drug reactions reported by an immunoallergology departmentCosta MJHerdeiro MTPolónia JJRibeiro-Vaz IBotelho CCastro ECernadas J. Objective: Characterization of the adverse drug reactions (ADR) reported by the immunoallergology department (IAD), Centro Hospitalar de São João (Porto), to the Northern Pharmacovigilance Centre (NPC). Methods: An observational, descriptive and retrospective study was conducted, based in a spontaneous report system. Participants were all the patients from the IAD, with suspected ADR, reported to NPC by specialists after the study was completed. Results: Studied population had a median age of 41 years, with the predominance of the female gender (73.2%). Allergic rhinitis and asthma were the most frequent comorbidities. All studied ADR were type B, 89.6% were serious, 86.4% unexpected and 2.6% associated with drugs that presented less than 2 years in the market. The most represented drug classes were the non-steroidal anti-inflammatory drugs (NSAIDs) (52.6%) and antibiotics (25.2%). Skin symptoms represented 61.2% of the reported complaints. About 52.9% of these ADR occurred in less than one hour after intake. The most frequent ADR treatment at the time of the reaction was drug interruption (86.2%), followed by the prescription of anti-histamines (42.2%). Conclusions: Reported ADR to NPC by the Drug Alert Unit were mainly serious, unexpected, associated with NSAIDs and antibiotics and related with marketing authorization medicines older than two years. These results could be very useful to develop strategies to prevent the clinical and economic consequences of ADR.https://www.pharmacypractice.org/journal/index.php/pp/article/view/1070/608Drug-Related Side Effects and Adverse ReactionsAdverse Drug Reaction Reporting SystemsInpatientsAnti-Inflammatory Agents Non-SteroidalAnti-Bacterial AgentsPortugal |
| spellingShingle | Costa MJ Herdeiro MT Polónia JJ Ribeiro-Vaz I Botelho C Castro E Cernadas J. Type B adverse drug reactions reported by an immunoallergology department Pharmacy Practice Drug-Related Side Effects and Adverse Reactions Adverse Drug Reaction Reporting Systems Inpatients Anti-Inflammatory Agents Non-Steroidal Anti-Bacterial Agents Portugal |
| title | Type B adverse drug reactions reported by an immunoallergology department |
| title_full | Type B adverse drug reactions reported by an immunoallergology department |
| title_fullStr | Type B adverse drug reactions reported by an immunoallergology department |
| title_full_unstemmed | Type B adverse drug reactions reported by an immunoallergology department |
| title_short | Type B adverse drug reactions reported by an immunoallergology department |
| title_sort | type b adverse drug reactions reported by an immunoallergology department |
| topic | Drug-Related Side Effects and Adverse Reactions Adverse Drug Reaction Reporting Systems Inpatients Anti-Inflammatory Agents Non-Steroidal Anti-Bacterial Agents Portugal |
| url | https://www.pharmacypractice.org/journal/index.php/pp/article/view/1070/608 |
| work_keys_str_mv | AT costamj typebadversedrugreactionsreportedbyanimmunoallergologydepartment AT herdeiromt typebadversedrugreactionsreportedbyanimmunoallergologydepartment AT poloniajj typebadversedrugreactionsreportedbyanimmunoallergologydepartment AT ribeirovazi typebadversedrugreactionsreportedbyanimmunoallergologydepartment AT botelhoc typebadversedrugreactionsreportedbyanimmunoallergologydepartment AT castroe typebadversedrugreactionsreportedbyanimmunoallergologydepartment AT cernadasj typebadversedrugreactionsreportedbyanimmunoallergologydepartment |